Stockscreener 앱 받기
2.24
6.28%
-0.15
시간 외 거래:
2.24
Creative Medical Technology Holdings Inc 주식(CELZ)의 최신 뉴스
12 Health Care Stocks Moving In Monday's After-Market SessionAlvotech (NASDAQ:ALVO), Anixa Biosciences - Benzinga
CELZ Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesFull Year Guidance - newsline.com
Anthropic Quietly Releases Claude Fable 5 to Public After Earlier ConcernsPreliminary Results - newsline.com
Hancock Whitney Q1 2026 Earnings: EPS Beats Estimates Modestly Amid Flat Revenue EnvironmentOperating Margin Analysis - newsline.com
CELZ Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentEarnings Revision Report - newsline.com
Spain Tourism Surges to Record as Travelers Shift from Middle EastShort-Term Outlook - newsline.com
Pro-Dex Inc. (PDEX) Edges Higher as Shares Trade Near ResistanceHedge Fund Favorites - newsline.com
CELZ Q1 2026 Earnings: Loss Per Share Narrows, Topping Analyst EstimatesEarnings Revision Downgrade - The Legal Advocate
CELZ Q1 2026 Earnings: Narrower Q1 Loss Fails to Lift Shares as Market Focuses on Cash RunwayFinancial Health Score - newsline.com
CELZ PE Ratio & Valuation, Is CELZ Overvalued - Intellectia AI
EPS Creative Health Technology Group Limited Announces Management Changes, Effective May 31, 2026 - marketscreener.com
Creative Medical Technology (CELZ) Edges Lower by 0.22% as Stock Consolidates Between Key LevelsStock Surge Alerts - The Legal Advocate
MFA Financial Inc. 8.875% Senior Notes due 2029 (MFAN) Q1 2026 Earnings: EPS Falls Just Short of Estimates, Bond Price Edges HigherProfit Cycle Analysis - The Legal Advocate
MIRA Pharmaceuticals Inc. (MIRA) Slips 8.66% to $1.05 as Technicals Test Key SupportLinear Regression - newsline.com
CELZ Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfit Guidance Range - The Legal Advocate
Critical Metals Corp (CRML) Slips 3.75% as Key Support Level Tests BuyersRSI Oversold Picks - The Legal Advocate
CELZ Stock Price, Quote & Chart | CREATIVE MEDICAL TECHNOLOGY (NASDAQ:CELZ) - ChartMill
Intercontinental Exchange (ICE) Edges Higher Amid Positive Volume TrendsLast Point Support - newsline.com
Creo Medical shares surge 27% on proposed sale of remaining European stake - Yahoo Finance
Japan Smaller Capitalization Fund (JOF) Edges Lower Amid Modest PullbackMAMA Signal - The Legal Advocate
Creative Medical Technology Holdings, Inc.Common Stock (NQ: CELZ - FinancialContent
Accel Entertainment (ACEL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Xtant Medical Q1 2026 Results: Revenue Guidance Raised, Balance Sheet Strengthened, Exclusive HEMOBLAST® Bellows Distribution Secured 12 - Minichart
QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million - Business Wire
Incannex Healthcare Wins MedTech Breakthrough Award for Innovative Obstructive Sleep Apnea Drug IHL-42X - Minichart
Leading Breast Surgical Oncologist Dr. Barry Roseman to Serve as Senior Medical Advisor to QT Imaging - Business Wire
United States shares higher at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com
CELZ (CreativeMed) EPS beats estimates but shares fall nearly 3% despite narrower losses.AI Stock Signals - Newser
Creative Medical Technology Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Creative Medical Technology (NASDAQ: CELZ) posts Q1 2026 loss, details cash use - Stock Titan
How CreativeMed (CELZ) prepares for market disruptions | Q3 2025: Earnings Beat EstimatesTrend Analysis - newser.com
Governor Newsom announces $1B in private investment generated through California Competes Tax Credits, driving business expansion in key industry sectors - California State Portal | CA.gov
Creative Medical Technology Holdings Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion - Yahoo Finance
Roth MKM Maintains Creative Medical Technology(CELZ.US) With Buy Rating, Maintains Target Price $20 - Moomoo
BZLEY Should I Buy - Intellectia AI
Creative Medical (CELZ) Reports Encouraging Pilot Study Results for Ultrasome Therapy - GuruFocus
Creative Medical (CELZ) Reports Promising Osteoarthritis Therapy Results - GuruFocus
BY Technical Analysis & Price Forecast - Intellectia AI
Creative Medical reports positive pilot study results for Ultrasome - Investing.com UK
Creative Medical reports positive pilot study results for Ultrasome By Investing.com - Investing.com Australia
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies - The Manila Times
Park Place Technologies Partners with Professional Athlete Genie Bouchard as 'Genie from IT” in New TV Commercial - The Manila Times
Uncertainty Around AI’s Impact on Careers Clouds Students’ College Decisions - The Manila Times
Cell-free knee arthritis therapy posts 93% response in pilot study - Stock Titan
Multiple BottomStock ScreenerCharts - Finviz
JXHLY Forecast — Price Prediction for 2026. Should I Buy JXHLY? - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NPSKY Technical Analysis & Stock Price Forecast - Intellectia AI
BHPCD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Iran Hormuz Strait Crisis: Oil Market Impact & Energy Investment Strategy 2026 - Intellectia AI
NAII Technical Analysis & Price Forecast - Intellectia AI
MITT Technical Analysis & Price Forecast - Intellectia AI
RWAY Technical Analysis & Price Forecast - Intellectia AI
Creative Medical Technology Holdings, Inc. 2025 Annual Report: Executive Summary, Compensation, and Compliance Disclosures - Minichart
IBEX Technical Analysis & Price Forecast - Intellectia AI
TOVXPrice, Charts & Blockchain Insights - Intellectia AI
Creative Medical (NASDAQ: CELZ) details 2025 pay, ownership and deals - Stock Titan
1.27%
1.43%
자본화:
|
볼륨(24시간):